Serious adverse events · children with juvenile idiopathic arthritis and flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment success (caries lesion arrest or restoration survival) · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · children with asymptomatic flat feet
Customised foot orthoses showed no clear difference in withdrawal due to adverse events compared with shoes (low certainty).
1 finding from 1 review
RR 1.05 [0.94, 1.19]
Studies not reported
Low
Adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · children with asymptomatic flat feet
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cognitive decline · older adults with cognitive impairment at baseline
1 finding from 1 review
Intervention not reported
Cohort studies ‐ 1 dose · children 9 months to 15 years old
The intervention probably leads to lower cohort studies ‐ 1 dose (moderate certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ Jeryl Lynn strain ‐ household contacts · children 9 months to 15 years old
The intervention probably leads to lower cohort studies ‐ Jeryl Lynn strain ‐ household contacts (moderate certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ encephalitis meningitis ‐ encephalitis meningitis risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ encephalitis meningitis ‐ encephalitis… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ herpes ‐ herpes risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ herpes ‐ herpes risk period (0 to 90… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ pneumonia ‐ pneumonia risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ pneumonia ‐ pneumonia risk period (0… (low certainty).
1 finding from 1 review
Intervention not reported
Self‐controlled case series ‐ miscellaneous viral infections ‐ miscellaneous viral infections risk period (0 to 90 days) · children 9 months to 15 years old
The intervention showed no clear difference in self‐controlled case series ‐ miscellaneous viral infections ‐… (low certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ Urabe strain ‐ unspecified numbers or at least 1 dose · children 9 months to 15 years old
The intervention may leads to lower cohort studies ‐ Urabe strain ‐ unspecified numbers or at least 1 dose (low certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ Rubini strain ‐ unspecified numbers or at least 1 dose · children 9 months to 15 years old
The intervention showed no clear difference in cohort studies ‐ Rubini strain ‐ unspecified numbers or at least 1… (low certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ mumps strain not reported or any strain · children 9 months to 15 years old
The intervention may leads to lower cohort studies ‐ mumps strain not reported or any strain (low certainty).
1 finding from 1 review
Intervention not reported
Cohort studies ‐ third dose versus 2 doses · children 9 months to 15 years old
The intervention showed no clear difference in cohort studies ‐ third dose versus 2 doses (low certainty).
1 finding from 1 review
Intervention not reported
Cohort studies secondary cases ‐ any strain · children 9 months to 15 years old
The intervention probably leads to lower cohort studies secondary cases ‐ any strain (moderate certainty).
1 finding from 1 review
Intervention not reported
MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ · children 9 months to 15 years old
The intervention leads to lower MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ (high certainty).
1 finding from 1 review
Intervention not reported
MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ · children 9 months to 15 years old
The intervention leads to lower MMRV randomised controlled trial ‐ any severity ‐ 2 doses ‐ (high certainty).
1 finding from 1 review